Cldn34c2, a member of the claudin family, holds a critical role in cellular function by participating in bicellular tight junction assembly and cell adhesion. The protein is primarily localized to the plasma membrane, where it contributes to the formation of tight junctions between adjacent cells. Tight junctions are crucial components of epithelial tissues, serving as barriers that regulate the passage of ions, molecules, and cells through the intercellular space. In particular, Cldn34c2's involvement in bicellular tight junction assembly underscores its significance in maintaining the integrity of these cellular barriers. The proper functioning of tight junctions is essential for diverse physiological processes, including the establishment of tissue boundaries, prevention of paracellular leakage, and regulation of cell polarity. Through its predicted role in cell adhesion, Cldn34c2 plays a crucial part in cellular interactions, influencing overall tissue architecture and function.
Inhibition of Cldn34c2 involves the modulation of various cellular processes and signaling pathways that contribute to tight junction assembly and cell adhesion. These mechanisms of inhibition target specific cellular components and pathways associated with Cldn34c2 function. For instance, compounds influencing actomyosin contractility, such as Rho kinase (ROCK) inhibitors, indirectly impact Cldn34c2-associated tight junction dynamics. Modulators of protein phosphorylation, including protein kinase C (PKC) inhibitors and broad-spectrum kinase inhibitors, alter the phosphorylation status of tight junction proteins, thereby affecting Cldn34c2 function in cell adhesion. Additionally, inhibitors of key signaling pathways, such as the PI3K-Akt pathway and the TGF-β receptor, disrupt downstream cascades linked to Cldn34c2, influencing its participation in bicellular tight junction assembly. The diverse array of inhibitors reflects the multifaceted nature of Cldn34c2's involvement in cellular processes, highlighting the intricate regulatory networks that govern tight junction formation and cell adhesion. Understanding these mechanisms of inhibition contributes to a comprehensive appreciation of Cldn34c2's role in cellular physiology and provides insights into potential strategies for modulating its function for various research purposes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | $257.00 $505.00 | 9 | |
HMG-CoA reductase inhibitor influencing cholesterol biosynthesis. Atorvastatin indirectly influences Cldn34c2 by modulating membrane composition, affecting bicellular tight junction assembly and cell adhesion. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Epidermal growth factor receptor (EGFR) inhibitor influencing signaling cascades. Gefitinib modulates intracellular signaling, indirectly impacting Cldn34c2 involvement in bicellular tight junction assembly and cell adhesion. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Topoisomerase I inhibitor affecting DNA structure. Camptothecin indirectly influences Cldn34c2 by disrupting DNA processes, impacting cell division and indirectly affecting bicellular tight junction assembly and cell adhesion. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Rho kinase (ROCK) inhibitor affecting cytoskeleton dynamics. Y-27632 modulates actomyosin contractility, indirectly impacting Cldn34c2-associated bicellular tight junction assembly and cell adhesion. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Broad-spectrum protein kinase inhibitor impacting tight junction proteins. Staurosporine modulates protein phosphorylation, indirectly altering Cldn34c2 involvement in bicellular tight junction assembly and cell adhesion. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
Myosin light chain kinase (MLCK) inhibitor affecting actomyosin contractility. ML-7 modulates tight junction-associated cytoskeletal dynamics, indirectly influencing Cldn34c2 function in bicellular tight junction assembly and cell adhesion. | ||||||
2-APB | 524-95-8 | sc-201487 sc-201487A | 20 mg 100 mg | $28.00 $53.00 | 37 | |
Modulator of intracellular calcium levels affecting tight junction dynamics. 2-Aminoethoxydiphenyl borate acts as a calcium channel blocker, indirectly influencing Cldn34c2-associated bicellular tight junction assembly and cell adhesion. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Janus kinase (JAK) inhibitor influencing tight junction protein expression. Ruxolitinib modulates JAK-STAT signaling, indirectly affecting Cldn34c2-associated bicellular tight junction assembly and cell adhesion. | ||||||
H-1152 dihydrochloride | 451462-58-1 | sc-203592 sc-203592A | 1 mg 5 mg | $104.00 $364.00 | 7 | |
p21-activated kinase (PAK) inhibitor impacting cytoskeleton organization. H1152 modulates actin dynamics, indirectly affecting Cldn34c2-associated bicellular tight junction assembly and cell adhesion. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
PI3-kinase inhibitor disrupting the PI3K-Akt signaling pathway. Wortmannin indirectly influences Cldn34c2 expression by blocking PI3-kinase activity, affecting downstream signaling cascades associated with cellular proliferation, survival, and gene transcription linked to Cldn34c2 function. | ||||||